Peter Thompson
Founder bei CORVUS PHARMACEUTICALS, INC.
Vermögen: - $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Richard Miller | M | 73 |
Angel Pharmaceuticals Co., Ltd.
 Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Angel Pharmaceuticals Co., Ltd. operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases. The company was founded by Richard Miller and Ted Wang on October 5, 2020 and is headquartered in Shanghai, China. | 14 Jahre |
| Kevin Koch | M | 63 |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 8 Jahre |
| Laura Shawver | M | 66 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 13 Jahre |
| Winston Kung | M | 48 | 7 Jahre | |
| Pratik Shah | M | 54 | 8 Jahre | |
| David J. Lockhart | M | 62 |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
| Peter Kolchinsky | M | 47 | 6 Jahre | |
| James Topper | M | 62 | 10 Jahre | |
| Leiv Lea | M | 70 |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Angel Pharmaceuticals Co., Ltd. operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases. The company was founded by Richard Miller and Ted Wang on October 5, 2020 and is headquartered in Shanghai, China. | 10 Jahre |
| Vickie Capps | F | 62 | 6 Jahre | |
| Adrian Rawcliffe | M | 52 | 9 Jahre | |
| Richard Lowenthal | M | 58 | 9 Jahre | |
| Alan Colowick | M | 61 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | 6 Jahre |
| Alan Russell | M | 54 | 7 Jahre | |
| Amy Burroughs | F | 53 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 5 Jahre |
| Tal Zaks | M | 58 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 8 Jahre |
| Elliot Norry | M | 61 | 9 Jahre | |
| Jon Root | M | 64 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 5 Jahre |
| Sheila Gujrathi | M | 53 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 3 Jahre |
| James Rickey | M | 45 | 7 Jahre | |
| Badreddin Edris | M | 37 | 7 Jahre | |
| Timothy J. Smith | M | - |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 3 Jahre |
| Jeffrey A. Ledbetter | M | 73 |
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | - |
| David Mott | M | 58 | 10 Jahre | |
| Michael Carulli | M | 74 | 4 Jahre | |
| John Reed | M | 65 | 4 Jahre | |
| R. Carruthers | M | 66 | 5 Jahre | |
| Vivek Sivathanu | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 4 Jahre |
| Jake Simson | M | 38 | 3 Jahre | |
| Remy Durand | M | 38 | 6 Jahre | |
| Jonathan Mandelbaum | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 4 Jahre |
| Laurie Stelzer | F | 56 | 4 Jahre | |
| Scott Morrison | M | 66 | 9 Jahre | |
| Kipyegon Kitur | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 6 Jahre |
| Bruce Turner | M | 60 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 Jahre |
| Kimberly McCutcheon Jablonski | F | - |
Cardioxyl Pharmaceuticals LLC
 Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
| Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 Jahre |
| Shehnaaz Suliman | M | 52 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | 2 Jahre |
| Stanford Peng | M | 53 | 7 Jahre | |
| Kirsten Flowers | F | 49 | 2 Jahre | |
| Temre Johnson | M | - | - | |
| Andy Meyer | M | 40 | 3 Jahre | |
| Sarina Tanimoto | M | 55 | 9 Jahre | |
| Robert Bell | M | - | 9 Jahre | |
| Ji Wang | F | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 4 Jahre |
| Deepika Jalota | M | 48 | 5 Jahre | |
| Clay Daniel Demarcus | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | - |
| Marie Debans | F | - | 4 Jahre | |
| Xiang Ming Cui | M | 55 | 5 Jahre | |
| Natasha Shervani | F | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | - |
| Natasha Hernday | F | 52 | 4 Jahre | |
| Christopher Peetz | M | 45 | 6 Jahre | |
| Alexander Fitzpatrick | M | 57 | 2 Jahre | |
| Kathleen McKereghan Deeley | F | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 17 Jahre |
| Klaus Veitinger | M | 62 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 17 Jahre |
| Ian Clark | M | 62 | 7 Jahre | |
| Brian Dorsey | M | 55 | 6 Jahre | |
| Robert Conway | M | 70 | 7 Jahre | |
| Phillip Schneider | M | 67 | 5 Jahre | |
| Carl Gordon | M | 59 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 29 Jahre |
| Terry Gould | M | 67 | 10 Jahre | |
| Mitchell Gold | M | 57 | 7 Jahre | |
| Joshua Golomb | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | - |
| Rajeev Dadoo | M | 54 | 3 Jahre | |
| Rishi Gupta | M | 46 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 21 Jahre |
| David Bonita | M | 48 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 20 Jahre |
| Laura Brege | F | 66 | 4 Jahre | |
| Wayne Gombotz | M | 64 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 Jahre |
| Linda Grais | M | 68 | 5 Jahre | |
| Richard Heyman | M | 66 | 4 Jahre | |
| Ali Behbahani | M | 47 | 10 Jahre | |
| Michael Kelly | M | 59 | 5 Jahre | |
| Douglas Cowart | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | 19 Jahre |
| Alana McNulty | F | 61 | 3 Jahre | |
| Saqib Islam | M | 54 | 2 Jahre | |
| Ted Wang | M | 57 |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Angel Pharmaceuticals Co., Ltd. operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases. The company was founded by Richard Miller and Ted Wang on October 5, 2020 and is headquartered in Shanghai, China. | 4 Jahre |
| Brendan Weber | M | - |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 7 Jahre |
| Lawrence Alleva | M | 74 | 9 Jahre | |
| Justin Chakma | M | 35 | 5 Jahre | |
| Charles Baum | M | 65 | 3 Jahre | |
| Julie Hambleton | M | 66 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 Jahre |
| Jonathan Fox | M | 66 | 1 Jahre | |
| R. Session | M | 45 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
| Ronald Borchardt | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | 3 Jahre |
| Steven Gillis | M | 71 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 4 Jahre |
| Jay Lichter | M | 62 | - | |
| Mina Sooch | F | 56 | 10 Jahre | |
| Robert E. Pelzer | M | 70 | 7 Jahre | |
| Francois Nader | M | 67 | 3 Jahre | |
| Sam Isaly | M | 79 |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | - |
| Michelle Burris | F | 58 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 4 Jahre |
| William Carson | M | 65 | 3 Jahre | |
| Nick Glover | M | 55 | 6 Jahre | |
| Jay Venkatesan | M | 52 | 5 Jahre | |
| Christopher Chai | M | 58 | 7 Jahre | |
| Martin Babler | M | 59 | 9 Jahre | |
| John Bencich | M | 47 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 3 Jahre |
| Floyd E. Romesberg | M | 58 | 5 Jahre | |
| Michelle Griffin | F | 58 |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 94 | 94,00% |
| Vereinigtes Königreich | 6 | 6,00% |
| China | 3 | 3,00% |
| Cayman Islands | 0 | -.--% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Peter Thompson
- Persönliches Netzwerk
